ISAL 2023 | The use of single-cell technologies to dissect AML heterogeneity

Ravi Majeti • 21 Mar 2023

ISAL 2023

Leukemia

Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, explains how single-cell technologies can help us understand the heterogeneity of acute myeloid leukemia (AML) and provide insights into drug resistance and therapeutic targeting. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

R.M. is on the Advisory Boards of Kodikaz Therapeutic Solutions, TenSixteen Bio, Roche, Cullgen, and 858 Therapeutics and is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences. R.M. receives research support from Gilead Sciences. R.M. is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics.